132 related articles for article (PubMed ID: 27499936)
21. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.
Kasymjanova G; MacDonald N; Agulnik JS; Cohen V; Pepe C; Kreisman H; Sharma R; Small D
Curr Oncol; 2010 Aug; 17(4):52-8. PubMed ID: 20697515
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
23. Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival innon-small-cell lung cancer.
Bacha S; Sghaier A; Habibech S; Cheikhrouhou S; Racil H; Chaouch N; Zaouri B; Chabbou A
Tunis Med; 2017 Dec; 95(12):229-235. PubMed ID: 29878284
[TBL] [Abstract][Full Text] [Related]
24. Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Zhang L; Xu Y; Shen J; He F; Zhang D; Chen Z; Duan Y; Sun J
Radiat Oncol; 2016 Apr; 11():60. PubMed ID: 27097970
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.
Pilkington G; Boland A; Brown T; Oyee J; Bagust A; Dickson R
Thorax; 2015 Apr; 70(4):359-67. PubMed ID: 25661113
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive value of serum C-reactive protein levels in patients with metastatic or locally recurrent gastric cancer.
Chen Z; Sun Y; Wang J; Shen X; Chen L; Zhuang Z
Int J Biol Markers; 2016 Jul; 31(3):e294-9. PubMed ID: 27174235
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
29. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
30. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
Qiu Y; Jiang J; Zhang M; Qin Y
Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
[TBL] [Abstract][Full Text] [Related]
32. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
33. C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
McFarland DC; Shaffer K; Breitbart W; Rosenfeld B; Miller AH
Cancer; 2019 Mar; 125(5):779-787. PubMed ID: 30521079
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
35. The impact of lung cancer resection surgery on fibrinogen and C-reactive protein and their relationship with patients outcomes: A prospective follow up study.
Araújo AS; Nogueira IC; Gomes Neto A; de Medeiros IL; Morano MT; da Silva GP; Santos FA; De Moraes Filho MO; Pereira ED
Cancer Biomark; 2016; 16(1):47-53. PubMed ID: 26484610
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
37. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
38. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
39. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
40. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
